2022 World Conference on Lung Cancer (ePosters)-EP16.02-003. Real World Experience and Feasibility of Tissue Informed CGP and ctDNA Testing in a Cohort of NSCLC Patients

EP16.02-003. Real World Experience and Feasibility of Tissue Informed CGP and ctDNA Testing in a Cohort of NSCLC Patients

Back to course

Pdf Summary

Researchers conducted a study to assess the feasibility and clinical utility of circulating tumor DNA (ctDNA) analysis in patients with non-small cell lung cancer (NSCLC) across different stages. They analyzed 41 patients with stage I-IV NSCLC who underwent ctDNA testing using a personalized, tumor-informed assay. Some patients also underwent comprehensive genomic profiling (CGP). The study found that ctDNA analysis was indicative of treatment response and congruent with clinical findings. The dynamics of ctDNA were also informative in detecting minimal residual disease (MRD) and providing early indications of relapse. CGP allowed for the identification of patients who may benefit from targeted therapies and informed clinical trial selection. The study showed the feasibility of performing both CGP and ctDNA testing using a single tissue sample. The findings highlight the potential of these approaches for guiding treatment decisions and personalizing systemic regimens in NSCLC. Further research is needed to evaluate the use of a combined CGP and ctDNA approach in adjuvant decision-making, surveillance monitoring, and treatment personalization. The study also presented case examples demonstrating the utility of ctDNA testing in monitoring treatment response and detecting recurrence in metastatic NSCLC patients. This real-world experience provides valuable insights into the clinical application of ctDNA analysis and its potential for improving patient outcomes.

Asset Subtitle

Georges Azzi

Meta Tag

Speaker Georges Azzi

Topic Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

Keywords

circulating tumor DNA

ctDNA analysis

non-small cell lung cancer

feasibility

clinical utility

comprehensive genomic profiling

minimal residual disease

targeted therapies

treatment response

recurrence